Axolotl Biologix and Carmell Therapeutics Merge to Pioneer Regenerative Medicine Advancements
Flagstaff's Axolotl Biologix merges with Carmell Therapeutics, a major move in regenerative medicine. $65 million initial value with potential for $75 million more in milestone payments. Pioneering innovations expected in soft tissue repair and orthopedics.